Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL

Key Points

• Amundi reduced its Exelixis position by 77.9% in the first quarter, selling 121,348 shares and retaining 34,398 shares valued at approximately $1.48 million.
• Other major institutions, including AQR Capital, UBS, Thrivent Financial and Goldman Sachs, increased their holdings, while institutional investors and hedge funds collectively own 85.27% of EXEL.
• Exelixis reported quarterly EPS of $0.91, beating estimates, and revenue increased 10.6% year over year to $628.7 million. However, analysts remain cautious: the consensus rating is Hold, with an average price target of $49.79 versus the recent share price near $54.

Amundi cut its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 77.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,398 shares of the biotechnology company's stock after selling 121,348 shares during the quarter. Amundi's holdings in Exelixis were worth $1,475,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of EXEL. AQR Capital Management LLC grew its position in Exelixis by 48.8% in the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company's stock worth $598,647,000 after purchasing an additional 4,477,029 shares during the last quarter. Norges Bank bought a new stake in shares of Exelixis in the fourth quarter valued at about $106,460,000. UBS Group AG grew its position in Exelixis by 100.1% during the third quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company's stock worth $109,654,000 after buying an additional 1,328,087 shares in the last quarter. Thrivent Financial for Lutherans grew its position in Exelixis by 1,821.0% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,188,105 shares of the biotechnology company's stock worth $52,075,000 after buying an additional 1,126,256 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Exelixis by 111.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,115,456 shares of the biotechnology company's stock valued at $92,720,000 after acquiring an additional 1,113,916 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter EPS of $0.91, ahead of the $0.85-$0.86 analyst consensus and up from $0.75 a year earlier. Revenue rose 10.6% year over year to approximately $628.7 million, while the company continues to benefit from its established cabozantinib business. Exelixis Q2 earnings
• Positive Sentiment: The company launched a new Phase 3 trial testing zanzalintinib in residual colorectal cancer, expanding the potential market for its pipeline and providing another long-term growth catalyst. Exelixis colorectal cancer trial
• Positive Sentiment: TD Cowen reaffirmed a Buy rating and a $55 price target, citing resilience in cabozantinib, cost discipline and upside from zanzalintinib despite near-term guidance pressure.
• Neutral Sentiment: Stifel raised its price target from $47 to $51 but retained a Hold rating. Its target remains below the recent trading level, suggesting limited near-term upside in the analyst’s view.
• Negative Sentiment: Exelixis lowered the midpoint of its 2026 revenue outlook by $50 million, primarily because the NET launch has been slower than expected. Although the EPS beat was encouraging, the revenue miss and reduced outlook are weighing on growth expectations. Exelixis 2026 guidance
• Negative Sentiment: Leerink Partners downgraded EXEL from Outperform to Market Perform and set a $52 price target, below the recent share price. Leerink Partners downgrade
• Negative Sentiment: Zacks Research maintains a Strong Sell rating and made small reductions to its FY2026-FY2028 EPS forecasts, including a FY2026 estimate of $3.12 versus the broader consensus of $3.15.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $54.07 on Friday. The firm's 50 day simple moving average is $54.17 and its 200 day simple moving average is $47.94. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $57.57. The company has a market capitalization of $13.59 billion, a price-to-earnings ratio of 17.00, a P/E/G ratio of 1.51 and a beta of 0.44.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to analyst estimates of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The firm's revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.75 EPS. Equities research analysts expect that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Insider Buying and Selling at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the company's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the transaction, the chief financial officer directly owned 952,317 shares of the company's stock, valued at approximately $47,615,850. This represents a 3.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 43,451 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total value of $2,187,757.85. Following the transaction, the executive vice president owned 594,741 shares of the company's stock, valued at approximately $29,945,209.35. This trade represents a 6.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 130,824 shares of company stock worth $6,555,231 in the last quarter. Company insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Truist Financial dropped their price objective on shares of Exelixis from $56.00 to $52.00 and set a "hold" rating for the company in a research note on Thursday. TD Cowen lifted their target price on shares of Exelixis from $51.00 to $55.00 and gave the company a "buy" rating in a research report on Wednesday, May 6th. Leerink Partners cut shares of Exelixis from an "outperform" rating to a "market perform" rating and set a $52.00 target price on the stock. in a research note on Thursday. Wall Street Zen lowered shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, UBS Group set a $55.00 price target on shares of Exelixis in a research note on Monday. Seven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Exelixis has a consensus rating of "Hold" and an average price target of $49.79.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source